Checkpoint Therapeutics Stock Price, News & Analysis (NASDAQ:CKPT)

$4.49 +0.38 (+9.25 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$4.11
Today's Range$4.09 - $4.51
52-Week Range$3.20 - $15.00
Volume22,757 shs
Average Volume47,556 shs
Market Capitalization$105.34 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics logoCheckpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CKPT
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio4.39%
Quick Ratio4.39%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.57 million
Price / Sales44.57
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$-22,460,000.00
Net Margins-1,319.73%
Return on Equity-94.82%
Return on Assets-81.08%

Miscellaneous

Employees7
Outstanding Shares25,510,000

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Where is Checkpoint Therapeutics' stock going? Where will Checkpoint Therapeutics' stock price be in 2018?

2 analysts have issued 1-year price targets for Checkpoint Therapeutics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $11.00 in the next year. View Analyst Ratings for Checkpoint Therapeutics.

Who are some of Checkpoint Therapeutics' key competitors?

How do I buy Checkpoint Therapeutics stock?

Shares of Checkpoint Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of Checkpoint Therapeutics stock can currently be purchased for approximately $4.49.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $105.34 million and generates $2.57 million in revenue each year. Checkpoint Therapeutics employs 7 workers across the globe.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Checkpoint Therapeutics (CKPT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  49 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  89
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Checkpoint Therapeutics (NASDAQ:CKPT) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.00$11.00N/AN/A
Price Target Upside: 138.61% upside138.61% upsideN/AN/A

Checkpoint Therapeutics (NASDAQ:CKPT) Consensus Price Target History

Price Target History for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/8/2017HC WainwrightInitiated CoverageBuy -> Buy$11.00HighView Rating Details
3/22/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyLowView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Checkpoint Therapeutics (NASDAQ:CKPT) Earnings History and Estimates Chart

Earnings by Quarter for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ CKPT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.28)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Checkpoint Therapeutics (NASDAQ:CKPT) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-1.2 EPS

Dividends

Dividend History for Checkpoint Therapeutics (NASDAQ:CKPT)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Checkpoint Therapeutics (NASDAQ CKPT)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Checkpoint Therapeutics (NASDAQ CKPT) News Headlines

Source:
DateHeadline
Zacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of "Strong Buy" from BrokeragesZacks: Checkpoint Therapeutics Inc (CKPT) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - February 12 at 3:34 AM
BRIEF-Argos Obtains Option To License PD1 Checkpoint InhibitorsBRIEF-Argos Obtains Option To License PD1 Checkpoint Inhibitors
www.reuters.com - February 6 at 4:33 PM
Checkpoint Therapeutics to Present at BIO CEO & Investor ConferenceCheckpoint Therapeutics to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 6 at 9:00 AM
 Checkpoint Therapeutics Inc (CKPT) Given Average Rating of "Strong Buy" by Brokerages Checkpoint Therapeutics Inc (CKPT) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 3 at 7:38 PM
 Checkpoint Therapeutics Inc (CKPT) Given Average Recommendation of "Strong Buy" by Brokerages Checkpoint Therapeutics Inc (CKPT) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 25 at 3:30 PM
Checkpoint Therapeutics (CKPT) vs. The Competition Financial AnalysisCheckpoint Therapeutics (CKPT) vs. The Competition Financial Analysis
www.americanbankingnews.com - January 24 at 9:28 PM
Analyzing Checkpoint Therapeutics (CKPT) and The CompetitionAnalyzing Checkpoint Therapeutics (CKPT) and The Competition
www.americanbankingnews.com - January 23 at 3:12 PM
Checkpoint Therapeutics (CKPT) Cut to "Hold" at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 22 at 9:18 PM
Checkpoint Therapeutics (CKPT) Rating Increased to Buy at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 19 at 8:44 PM
Zacks Investment Research Lowers Checkpoint Therapeutics (CKPT) to HoldZacks Investment Research Lowers Checkpoint Therapeutics (CKPT) to Hold
www.americanbankingnews.com - January 10 at 7:46 PM
 Checkpoint Therapeutics Inc (CKPT) Given $15.50 Consensus Target Price by Brokerages Checkpoint Therapeutics Inc (CKPT) Given $15.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - January 9 at 7:58 AM
Checkpoint Therapeutics (CKPT) Upgraded by Zacks Investment Research to "Buy"Checkpoint Therapeutics (CKPT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - January 7 at 8:12 PM
Checkpoint Therapeutics (CKPT) Lowered to "Hold" at Zacks Investment ResearchCheckpoint Therapeutics (CKPT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 3 at 8:40 PM
Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018Checkpoint Therapeutics to Participate in LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
finance.yahoo.com - December 14 at 9:01 AM
Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor MicroenvironmentPionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
www.bizjournals.com - December 13 at 9:10 AM
Checkpoint Therapeutics (CKPT) Receives New Coverage from Analysts at HC WainwrightCheckpoint Therapeutics (CKPT) Receives New Coverage from Analysts at HC Wainwright
www.americanbankingnews.com - December 8 at 11:50 PM
Immune Checkpoint Inhibitors Market to Collect Revenues US$ 30,000 Mn by 2026 End - Persistence Market ResearchImmune Checkpoint Inhibitors Market to Collect Revenues US$ 30,000 Mn by 2026 End - Persistence Market Research
www.bizjournals.com - November 27 at 6:16 PM
Zacks Investment Research Upgrades Checkpoint Therapeutics, Inc. (CKPT) to "Buy"Zacks Investment Research Upgrades Checkpoint Therapeutics, Inc. (CKPT) to "Buy"
www.americanbankingnews.com - November 23 at 5:58 PM
Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional SharesMirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
www.bizjournals.com - November 20 at 6:19 PM
Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor ProgramsMirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs
www.thestreet.com - November 13 at 10:44 PM
Mirati Therapeutics Mocetinostat Included In Stand Up To Cancers Cutting-Edge Clinical Trial Initiative For NSCLC PatientsMirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients
www.bizjournals.com - October 12 at 6:03 PM
Five Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITCFive Prime Therapeutics (FPRX) Says Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at SITC
www.streetinsider.com - October 11 at 11:48 PM
BRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancersBRIEF-Checkpoint Therapeutics initiates phase 1 study of antibody CK-301 for metastatic cancers
www.reuters.com - October 6 at 5:30 PM
Checkpoint Therapeutics (CKPT) Starts CK-301 TrialsCheckpoint Therapeutics (CKPT) Starts CK-301 Trials
finance.yahoo.com - October 5 at 11:21 AM
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceCheckpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 6:02 PM
Leap Therapeutics To Present At The 2017 Ladenburg Thalmann Healthcare ConferenceLeap Therapeutics To Present At The 2017 Ladenburg Thalmann Healthcare Conference
www.thestreet.com - September 19 at 10:15 PM
Mirati Therapeutics stock soars on heavy volume after positive cancer treatment trial resultsMirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial results
www.marketwatch.com - September 15 at 10:40 PM
Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung CancerMirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer
www.bizjournals.com - September 14 at 5:59 PM
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung CancerCheckpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer
finance.yahoo.com - September 11 at 5:55 PM
Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceCheckpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 5 at 6:47 PM

SEC Filings

Checkpoint Therapeutics (NASDAQ:CKPT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Checkpoint Therapeutics (NASDAQ CKPT) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.